Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanosphere Inc.

This article was originally published in Start Up

Executive Summary

Gold nanoparticles studded with oligonucleotides form the basis of Nanosphere Inc.'s molecular detection systems. The company claims its lead product can rapidly detect SNPs from a blood sample without PCR and with minimal preparation. Nanosphere has no intentions of entering the discovery arena or of collecting the kinds or volumes of data typical for high-density microarrays: it will develop assays only for clinically validated biomarkers.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel